NASDAQ:CDXS Codexis (CDXS) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CDXS Stock Alerts $2.94 +0.08 (+2.80%) (As of 02:50 PM ET) Add Compare Share Share Today's Range$2.88▼$3.0350-Day Range$2.69▼$4.6552-Week Range$1.45▼$4.91Volume115,795 shsAverage Volume561,509 shsMarket Capitalization$206.68 millionP/E RatioN/ADividend YieldN/APrice Target$6.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Codexis alerts: Email Address Codexis MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside131.3% Upside$6.80 Price TargetShort InterestBearish3.39% of Shares Sold ShortDividend StrengthN/ASustainability-3.67Upright™ Environmental ScoreNews Sentiment0.48Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.06 out of 5 starsMedical Sector359th out of 910 stocksIndustrial Organic Chemicals Industry9th out of 18 stocks 3.3 Analyst's Opinion Consensus RatingCodexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCodexis has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.39% of the outstanding shares of Codexis have been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Codexis has recently increased by 3.93%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Previous Next 2.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCodexis has received a 14.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Industrial enzymes for pharmaceuticals", "Biochemical assay kits", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Codexis is -3.67. Previous Next 1.9 News and Social Media Coverage News SentimentCodexis has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Codexis this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Codexis to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.30% of the stock of Codexis is held by insiders.Percentage Held by Institutions78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Codexis are expected to decrease in the coming year, from ($0.60) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Codexis Stock (NASDAQ:CDXS)Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Read More CDXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDXS Stock News HeadlinesApril 20, 2024 | americanbankingnews.comCodexis, Inc. (NASDAQ:CDXS) Given Average Rating of "Moderate Buy" by BrokeragesApril 19, 2024 | finance.yahoo.comCodexis, Inc. (CDXS)April 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 19, 2024 | americanbankingnews.comCodexis (NASDAQ:CDXS) Shares Cross Above 200 Day Moving Average of $2.70April 18, 2024 | globenewswire.comCodexis to Report First Quarter 2024 Financial Results on May 2April 15, 2024 | americanbankingnews.comFinancial Review: Codexis (NASDAQ:CDXS) & Golden Arrow Merger (NASDAQ:GAMC)April 11, 2024 | globenewswire.comCodexis Appoints Carole Cobb, MBA, to Strategic Advisory BoardMarch 30, 2024 | finance.yahoo.comFavourable Signals For Codexis: Numerous Insiders Acquired StockApril 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.March 19, 2024 | seekingalpha.comAQST,CDXS and STI are among after hour moversMarch 1, 2024 | msn.comBenchmark raises Codexis to buy; cites Q4 earnings, guidanceMarch 1, 2024 | msn.comBenchmark Upgrades Codexis (CDXS)February 29, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Codexis (CDXS)February 29, 2024 | finance.yahoo.comCodexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finanznachrichten.deCodexis, Inc.: Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 29, 2024 | finance.yahoo.comQ4 2023 Codexis Inc Earnings CallFebruary 28, 2024 | benzinga.comRecap: Codexis Q4 EarningsFebruary 28, 2024 | msn.comCodexis GAAP EPS of -$0.10 beats by $0.04, revenue of $26.56M beats by $7.63MFebruary 28, 2024 | finance.yahoo.comCodexis Inc (CDXS) Reports Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | globenewswire.comCodexis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | theglobeandmail.comBiotech Rallied Strongly On Exclusive Licensing AgreementFebruary 27, 2024 | marketwatch.comCodexis Shares Up 31% on Roche Licensing AgreementFebruary 27, 2024 | msn.comCodexis Q4 2023 Earnings PreviewFebruary 26, 2024 | msn.comCodexis stock climbs 11% on Roche licensing deal for DNA ligasesFebruary 26, 2024 | globenewswire.comCodexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with RocheFebruary 26, 2024 | globenewswire.comCodexis to Participate in TD Cowen 44th Annual Health Care ConferenceFebruary 20, 2024 | finance.yahoo.comCodexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory BoardSee More Headlines Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Industrial organic chemicals Sub-IndustryBiotechnology Current SymbolNASDAQ:CDXS CUSIP19200510 CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees174Year FoundedN/APrice Target and Rating Average Stock Price Target$6.80 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+132.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,240,000.00 Net Margins-108.69% Pretax Margin-108.59% Return on Equity-47.58% Return on Assets-28.46% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.53 Sales & Book Value Annual Sales$70.14 million Price / Sales2.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book2.36Miscellaneous Outstanding Shares70,300,000Free Float65,875,000Market Cap$205.98 million OptionableOptionable Beta2.01 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Stephen George Dilly MBBS (Age 64)Ph.D., President, CEO & Director Comp: $753.61kMr. Kevin Norrett M.B.A. (Age 51)M.S., Chief Operating Officer Comp: $507.28kMs. Margaret Fitzgerald J.D. (Age 53)Chief Legal and Compliance Officer, General Counsel & Secretary Comp: $300.03kMr. Sriram Ryali M.B.A. (Age 42)Chief Financial Officer Carrie McKimDirector of Investor RelationsMs. Karen Frechou-ArmijoSenior VP & Head of Human ResourcesDr. Stefan Lutz Ph.D.Senior Vice President of ResearchMr. Robert Sato M.B.A.Ph.D., Senior Vice President of Pharmaceutical Development, Quality & RegulatoryMore ExecutivesKey CompetitorsVaccitechNASDAQ:VACCScilexNASDAQ:SCLXAtossa TherapeuticsNASDAQ:ATOSProfound MedicalNASDAQ:PROF908 DevicesNASDAQ:MASSView All CompetitorsInsiders & InstitutionsGSA Capital Partners LLPBought 420,977 shares on 2/16/2024Ownership: 1.199%Opaleye Management Inc.Bought 1,926,625 shares on 2/15/2024Ownership: 4.363%Aristides Capital LLCBought 61,900 shares on 2/13/2024Ownership: 0.089%Tower Research Capital LLC TRC Bought 13,203 shares on 2/13/2024Ownership: 0.022%Private Advisor Group LLCBought 7,065 shares on 2/6/2024Ownership: 0.271%View All Insider TransactionsView All Institutional Transactions CDXS Stock Analysis - Frequently Asked Questions Should I buy or sell Codexis stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CDXS shares. View CDXS analyst ratings or view top-rated stocks. What is Codexis' stock price target for 2024? 6 equities research analysts have issued twelve-month price objectives for Codexis' shares. Their CDXS share price targets range from $4.00 to $10.00. On average, they expect the company's share price to reach $6.80 in the next twelve months. This suggests a possible upside of 131.3% from the stock's current price. View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts. How have CDXS shares performed in 2024? Codexis' stock was trading at $3.05 at the beginning of the year. Since then, CDXS shares have decreased by 3.6% and is now trading at $2.94. View the best growth stocks for 2024 here. When is Codexis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CDXS earnings forecast. How can I listen to Codexis' earnings call? Codexis will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13726635". How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) announced its earnings results on Wednesday, February, 28th. The biotechnology company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.18. The biotechnology company earned $26.56 million during the quarter, compared to the consensus estimate of $24.73 million. Codexis had a negative trailing twelve-month return on equity of 47.58% and a negative net margin of 108.69%. What ETF holds Codexis' stock? Jacob Forward ETF holds 11,844 shares of CDXS stock, representing 1.17% of its portfolio. What guidance has Codexis issued on next quarter's earnings? Codexis issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $56.0 million-$64.0 million, compared to the consensus revenue estimate of $58.9 million. What is John J. Nicols' approval rating as Codexis' CEO? 25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS). How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDXS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
